Analyst, Performance Suite Analytics | {"ats": "workday", "city": null, "state": null, "job_id": "/job/Work-at-Home/Analyst--Performance-Suite-Analytics_JR-915497-1", "remote": false, "category": "oth

company_statement / Sep 15, 2026 / receipt

Migrating to adjusted construct with narrower corridors, with two-thirds of expected Specialty PS revenue covered by adjusted features effective 1/1/25.

ir_statement / Sep 15, 2026 / receipt

This change is expected to be Adjusted EBITDA accretive, with approximately ~$500M y/y expected revenue impact vs. 2024.

ir_statement / Sep 15, 2026 / receipt

Contracting efforts since November result in more than two-thirds of Specialty PS revenue covered by all adjusted features effective 1/1/25

ir_statement / Sep 15, 2026 / receipt

Target mature margin 12-18% Modestly lower, e.g., ~10%

ir_statement / Sep 15, 2026 / receipt

Achieved targeted $100M in expected earnings improvement from PS negotiations, fully contracted.

ir_statement / Sep 15, 2026 / receipt

Currently forecasting oncology expenses after management to increase by 12% for 2025, compared to historical expectations of ~8%

ir_statement / Sep 15, 2026 / receipt

Expect stabilization of medical costs.

ir_statement / Sep 15, 2026 / receipt

Technology & Services: Expect >80% Adjusted EBITDA contribution from T&S in 2025, anticipating expanding gross margins into 2026 from increased process automation and efficiency gains.

ir_statement / Sep 15, 2026 / receipt

our ability to effectively manage our growth and maintain an efficient cost structure, and to successfully implement cost cutting measures

ir_statement / Sep 15, 2026 / receipt

our anticipated expanding gross margins into 2026 from increased process automation and efficiency gains

ir_statement / Sep 15, 2026 / receipt

our expected +$100-105m improvement to Adjusted EBITDA as a result of Performance Suite negotiations

ir_statement / Sep 15, 2026 / receipt